PBLA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 geg. 2024 @ 17:30):

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer...

Stats
Šios dienos apimtis	33 279.00
Vidutinė apimtis	139 879
Rinkos kapitalizacija	2.08M
EPS	$0 ( 2024-05-15 )
Kita pelno data	( $-2.07 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0240 (5.61%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-08	Goldman Sachs Group Inc	Sell	72 874	Common Stock
2023-11-07	Goldman Sachs Group Inc	Buy	0	Common Stock
2023-09-12	Jacob Jeffrey E.	Sell	275	Common Stock
2023-03-27	Simpson Jennifer K.	Buy	99 383	Stock Option (right to buy)
2023-03-27	Horvath Susan	Buy	34 369	Stock Option (right to buy)

INSIDER POWER
61.64
Last 76 transactions
Buy: 2 117 070 \| Sell: 358 529

Panbela Therapeutics, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Panbela Therapeutics, Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-25.65M (0.00 %)
EPS:	$-232 430

FY	2023
Pajamos:	$0
Bruto pelnas:	$-25.65M (0.00 %)
EPS:	$-232 430

FY	2022
Pajamos:	$0
Bruto pelnas:	$-35.73M (0.00 %)
EPS:	$-40 749

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-34.62

Financial Reports:

No articles found.

Panbela Therapeutics, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Panbela Therapeutics,

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.